The Trillion-Dollar ROI Reality Check The honeymoon phase of the artificial intelligence boom is hitting a brutal wall of fiscal reality. For the past year, the narrative suggested that AI would effortlessly replace high-cost human capital, driving margins to the moon. However, the data emerging from the front lines tells a different story. Scott Galloway points out a staggering paradox: Uber incinerated its entire 2026 AI budget in a mere four months, while Microsoft is actively cancelling Claude code licenses because they’ve become too expensive to maintain. When Nvidia executives admit the cost of compute is now 'far beyond' the cost of employees, the entire substitution thesis collapses. We are seeing a 1999-style intoxication where companies feel forced to mention AI in every earnings call, yet a recent MIT study reveals that only 5% of projects using tokens can be linked to a tangible return by CFOs. The market is waiting for the first major Fortune 500 CEO to break rank and admit that procurement is scaling back because the math simply doesn't work. Hollywood Rejects the Replacement Narrative While Silicon Valley obsessives fear a total displacement of creatives, Netflix co-CEO Ted Sarandos argues that the industry is overestimating the threat. AI is fundamentally built to provide the most predictable outcome—a mathematical average of what has already been done. In storytelling, predictability is the enemy. Sarandos highlights that writers are already using Claude not as a replacement, but as a high-speed sparring partner to bounce ideas off of. In production, the technology is driving efficiency in 'previs' and safety-critical stunt planning, but it isn't writing the next hit series. When the cost of a script is only 1% of a production budget, the incentive to automate the 'soul' of a project for a marginal saving is non-existent. The real value lies in the human capacity for the original and the unexpected, something no LLM is designed to replicate. GLP-1s Outpace the Silicon Hype While AI struggles with ROI, a different disruption is delivering universal results. David Ricks, CEO of Eli Lilly, highlights that GLP-1 drugs like Zepbound are achieving something rare in medicine: universal efficacy. Unlike most drugs that work on averages, these products are fundamentally altering the biological baseline for obesity, a nodal condition for over 200 chronic diseases. This isn't just about weight loss; it's about a structural shift in longevity and healthcare costs that could prove far more transformative to the global economy than a chatbot. The Strategic Failure in Iran Four months into the Iran War, the strategic 'precision' promised at the outset has dissolved into a quagmire of Iraq-like proportions. Scott Galloway, who initially supported military action, has publicly reversed his stance, labeling the intervention a national disaster. The failure to disrupt oil supplies or force a deal has left the IRGC emboldened, sensing a complete victory as leadership fails to own the tactical errors of a campaign that has fueled global inflation and squandered international goodwill.
Eli Lilly
Companies
Mar 2025 • 1 videos
High activity month for Eli Lilly. Chris Williamson among the most active voices, with 1 videos across 1 sources.
Nov 2025 • 1 videos
High activity month for Eli Lilly. The Compound among the most active voices, with 1 videos across 1 sources.
Jan 2026 • 1 videos
High activity month for Eli Lilly. The Prof G Pod – Scott Galloway among the most active voices, with 1 videos across 1 sources.
Feb 2026 • 4 videos
High activity month for Eli Lilly. The Prof G Pod – Scott Galloway and PowerfulJRE among the most active voices, with 4 videos across 2 sources.
Mar 2026 • 1 videos
High activity month for Eli Lilly. The Prof G Pod – Scott Galloway among the most active voices, with 1 videos across 1 sources.
Jun 2026 • 1 videos
High activity month for Eli Lilly. The Prof G Pod – Scott Galloway among the most active voices, with 1 videos across 1 sources.
The Prof G Pod – Scott Galloway (5 mentions) notes Eli Lilly's strong financial performance and upward revisions to its 2026 guidance, while The Compound (1 mention) acknowledges Eli Lilly's part in the stock market's performance.
- Jun 5, 2026
- Mar 16, 2026
- Feb 27, 2026
- Feb 5, 2026
- Feb 5, 2026
The High Stakes of Hyperscale Ambition Global markets are currently wrestling with a profound contradiction: record-breaking revenues met with investor skittishness. Google recently reported annual revenue exceeding $400 billion, a historic milestone fueled by a 48% surge in cloud services. Yet, the narrative quickly shifted from celebration to scrutiny as the company announced a massive capital expenditure (capex) forecast of $175 billion to $185 billion for the coming year. This aggressive "front-footed" growth strategy represents an attempt to secure dominance in the generative AI era, but it requires investors to stomach a multi-year digestion period before realizing meaningful returns. We have exited the 2023 "year of discipline" and re-entered a heavy investment cycle. While the market initially reacted with a 7% after-hours selloff, the recovery suggests a growing, albeit nervous, acceptance that these expenditures are the entry fee for the next decade of technological relevance. The infrastructure build-out validates the astronomical valuations of hardware providers like Nvidia, but for the hyperscalers themselves, the next three years represent a steep hill to climb before reaching the "harvest mode" where stock performance typically peaks. The Software Sector Purge: Real Threat or Market Panic? The enterprise software sector is currently the epicenter of market dislocation. In a single week, a brutal selloff erased $300 billion in market value across stalwarts like Salesforce, ServiceNow, and Workday. The catalyst? A fear that AI is not merely an enhancement but a fundamental displacer of the seat-based licensing model. If Anthropic's Claude can automate domains ranging from legal work to customer support, the traditional SaaS value proposition appears vulnerable. However, history suggests this "sell everything" mentality is often premature. We saw this exact pattern with the arrival of ChatGPT, when analysts prematurely declared the death of search. Instead, AI integration boosted Google to new heights. The current software rout likely represents a cleansing process. We will see "Macy's or Circuit City" equivalents in the software world—companies that weren't robust to begin with—fall away, while high-quality firms that successfully integrate AI into their product stacks will emerge stronger. This is a period of "sorting the rubble" to identify Dislocated High-Quality (DHQ) companies. The Divergent Paths of GLP-1 Dominance In the pharmaceutical sector, the battle for the obesity market has revealed a startling divergence between Eli Lilly and Novo Nordisk. Despite both companies navigating the same regulatory and pricing pressures, Eli Lilly saw its stock climb 10% on the back of massive volume growth, while Novo Nordisk cratered 18%. The market is increasingly viewing Eli Lilly as the ultimate winner of the injectable race, even as it prepares to enter the oral medication market. Novo Nordisk is suffering from "first-mover friction." While they have successfully transitioned hundreds of thousands of patients to oral therapies, the financial profile is less attractive due to lower price points and significant market share erosion. The stock is currently trading near 2021 levels, effectively erasing the gains of the GLP-1 craze. This suggests that in high-growth sectors, early innovation is insufficient; one must also maintain the pricing power and volume scale required to offset inevitable legislative and competitive headwinds. Antitrust and the Streaming Hegemony On Capitol Hill, the proposed merger between Netflix and Warner Bros. Discovery has faced a chaotic reception. While senators frequently diverted the discussion toward political bias and content "wokeness," the underlying antitrust concerns remain centered on the consolidation of the streaming landscape. The companies argue their true competition isn't each other, but the attention-grabbing algorithms of TikTok and YouTube. This argument represents a strategic shift in how tech giants define their markets to evade regulatory blocks. By positioning themselves as underdogs against the "short-form" giants, Netflix and Warner Bros. Discovery hope to justify a mega-merger that would otherwise look like a monopoly. While the Senate hearing serves as a symbolic artifact, the real determination lies with the Department of Justice, where the ideological battle between anti-consolidation and global competitiveness will ultimately decide the fate of traditional media.
Feb 5, 2026The Shift from Chatbots to Physical AI Integration The technological landscape is undergoing a critical transition as the focus moves from digital-only generative tools to "physical AI." Nvidia is at the center of this shift, using the CES stage to signal that the "ChatGPT moment" for robotics and autonomous systems has arrived. By putting its Reuben architecture into full production and partnering with Mercedes-Benz for vehicle integration, Nvidia is moving beyond the data center and into the driveway. This evolution represents a strategic pivot where chips are no longer just processing text and images but are managing real-world physics and complex autonomy. The Data Flywheel and Vertical Specialization Nvidia’s foray into autonomous vehicles and robotics is less about competing directly with Tesla for market share and more about securing a proprietary data flywheel. By open-sourcing underlying models and adopting an "Android-style" approach for cars, Nvidia gains access to vast streams of real-world data. This intelligence feeds back into their core business, informing the design of future specialized silicon. They are sacrificing vertical dominance in cars to ensure their hardware remains the indispensable backbone of all physical AI applications. The Rise of the Reverse Aqua-Hire A new M&A trend is emerging in the AI sector: the reverse aqua-hire. The recent Nvidia acquisition of Grock talent—while leaving the corporate shell intact—highlights a desperate race for specialized human capital. Jensen Huang targeted Jonathan Ross not for his company’s balance sheet, but for his expertise in AI inference. Solving the Inference Latency Problem While GPUs dominate the training phase of AI, the industry is hitting a wall with inference—the act of running those models in real-time. Startups have been outperforming legacy hardware in speed and efficiency during this phase. By absorbing the minds behind the TPU and the Grock chip, Nvidia is attempting to eliminate its one structural weakness before inference workloads explode across millions of consumer devices and wearables. Democratizing Metabolic Health: The Oral GLP-1 Pivot Novo Nordisk has fundamentally altered the competitive landscape of the obesity market by launching an oral Wegovy pill. This move addresses the primary psychological barrier to adoption: needle phobia. With roughly 63% of adults experiencing some level of needle anxiety, the transition from an injectable to a daily pill expands the addressable market from the clinically obese to the broader wellness-seeking population. Pricing Strategy as a Market Disruption The pricing of the Wegovy pill—ranging from $149 to $299 per month—represents a aggressive play for the out-of-pocket consumer. This is a fraction of the cost of current injectables and positions the drug as a direct competitor to high-end gym memberships and luxury wellness programs. By lowering the financial and physical barriers to entry, Novo Nordisk is betting on massive volume to offset lower margins per unit. Competitive Chasm in Healthcare Equities The valuation gap between Novo Nordisk and Eli Lilly has become a defining feature of healthcare markets. While Eli Lilly has enjoyed a trillion-dollar market cap premium, Novo Nordisk has traded at multi-year lows despite holding a dominant position in the oral market. This chasm suggests that the market may have underpriced the potential of the pill. If Novo can capture the 40% of the U.S. population currently living with obesity through a non-invasive, low-cost daily treatment, the current valuation gap will likely compress as the story shifts from niche medical treatment to a mass-market consumer staple.
Jan 7, 2026The Architecture of the Roaring 2020s Wealth management requires a steady hand and a long-term lens. While daily market fluctuations often dominate the headlines, the underlying structural shifts in the American economy suggest a period of remarkable resilience. This decade, often referred to as the **Roaring 2020s**, draws striking parallels to the 1920s, characterized by rapid technological adoption and a post-pandemic surge in productivity. Unlike the eventual collapse seen a century ago, the current trajectory is supported by a more robust banking system and a consumer base with unprecedented net worth. Economist Ed Yardeni posits that the S&P 500 could reach the 10,000 mark by the end of 2029. This is not a figure pulled from thin air. It is based on a fundamental progression of operating earnings, moving from roughly $268 per share today to an estimated $450 or $500 by the decade's end. When you apply a price-to-earnings (PE) multiple of 20 to these earnings, the math for a 10,000 target becomes self-evident. This growth depends on the continued ability of corporations to expand profit margins through productivity gains, largely fueled by the integration of artificial intelligence across all business sectors. Demographics and the New Consumer Reality The resilience of the current economy is frequently misunderstood because analysts tend to view consumers as a monolith. In reality, the spending power is concentrated among Baby Boomers, who hold approximately $80 trillion in net worth. This generation is not just retiring; they are actively spending on healthcare, travel, and leisure. Crucially, they are acting as a private financial buffer for younger generations, assisting with mortgage down payments and education costs. This intergenerational wealth transfer creates a floor for consumer demand that traditional interest rate hikes have struggled to penetrate. Higher interest rates, which typically dampen economic activity, have actually benefited this wealthy cohort. Many retirees are enjoying the highest yields on their cash and fixed-income portfolios in decades. While younger families face affordability crises in housing and insurance, the aggregate economy remains buoyed by a segment of the population that is less sensitive to borrowing costs and more focused on asset appreciation. This demographic shift is a cornerstone of the sustainable growth narrative, providing a level of stability that few anticipated at the start of the decade. The Artificial Intelligence Rerate Technology remains the primary engine of the market, but the "one big trade" era of the **Magnificent Seven** is fracturing. We are witnessing a significant dispersion among tech giants as the market begins to distinguish between pure infrastructure providers and companies successfully integrating AI into their vertical stacks. Alphabet has emerged as a standout, recently trading at a premium to Nvidia on a forward PE basis for the first time in years. This shift reflects a growing appreciation for Alphabet's vertical integration, from its proprietary TPU chips to its Gemini AI models. Nvidia, while still the undisputed leader in GPUs, has faced recent volatility as questions arise regarding the depreciation schedules of its hardware and the sustainability of its massive revenue growth. Short sellers have attempted to draw comparisons between the current AI build-out and historical accounting scandals, but the fundamental difference lies in economic soundess. Unlike the fiber-optic boom of the late 90s, today's AI infrastructure is being purchased by the most profitable companies in history with real cash flows. The volatility we see today is a healthy rerating process, not the bursting of a terminal bubble. The Digital Asset Treasury Evolution A new category of publicly traded companies has emerged, led by MicroStrategy (now known simply as Strategy). This model involves using equity and debt capital to aggressively accumulate Bitcoin. For a period, Strategy traded at a significant premium to its Net Asset Value (NAV), sometimes as high as 2.8 times its holdings. Recently, that premium has evaporated, with the stock trading at a discount to the value of its underlying digital assets. This shift highlights a critical lesson in investor psychology: the difference between wanting an asset and wanting the performance of an asset. When the parabolic move in the stock slows, the FOMO (fear of missing out) dissipates, often leaving the stock undervalued relative to its holdings. Furthermore, institutional pressures, such as potential exclusion from MSCI indices, create temporary selling pressure. Prudent investors recognize that these technical dislocations often provide better entry points than the heights of a speculative frenzy. The long-term viability of the "digital treasury" model will depend on whether these companies can continue to acquire assets faster than they dilute their shareholder base. Redefining the Bear Market There is a persistent fear that we are "due" for a massive crash simply because it has been 16 years since a 40% drawdown. However, a deeper look at market history reveals that 40% drops are almost exclusively reserved for recessionary periods. In the absence of a sustained economic contraction, the market more frequently experiences 19% to 20% "quick" bear markets. We have seen five such drawdowns in the last six years alone. These are painful in the moment but historically brief, lasting an average of five months compared to the eleven-month grind of a recessionary bear market. For wealth management, the distinction is vital. If the economy is not in recession, waiting for a "knockout punch" that never comes is a recipe for missed opportunity. Diversification into sectors like healthcare provides a necessary balance. Companies like Eli Lilly have transformed from stagnant pharma giants into trillion-dollar growth stories through breakthroughs in metabolic medicine. The growth of the GLP-1 market is not just a trend; it is a fundamental shift in global healthcare spending that mirrors the scale of the AI revolution in tech. Conclusion: The Path to 2030 The road to a 10,000 S&P 500 will not be a straight line. It will be marked by sector rotations, technical reratings, and the occasional "minor" meltdown. However, the combination of a productivity boom, a wealthy and spending retiring generation, and the resilience of corporate earnings creates a compelling case for optimism. True wealth is built by understanding these structural tailwinds and remaining disciplined through the inevitable noise of the daily ticker. As we look toward the 2030s, the goal remains the same: thoughtful cultivation of assets in an economy that has proven it can absorb shocks and continue its upward trajectory.
Nov 25, 2025The Hidden Evolution of Our World We often find ourselves trapped in the immediate cycle of news, missing the profound tectonic shifts happening beneath the surface. Naval Ravikant suggests that while the media fixates on the temporary, historians will look back at this decade as a period of radical transformation. Recognizing these shifts allows us to move from passive observers to intentional participants in our own growth and safety. Medicine in the Dark Ages Our current medical system relies heavily on intervention rather than deep understanding. We operate in a "Stone Age" of biology, where removing organs like the gallbladder or appendix is seen as a simple fix rather than a failure of systemic knowledge. The lack of robust explanatory theories beyond basic genetics means we often treat symptoms without grasping the underlying mechanisms. True resilience requires us to demand better innovation and perhaps, like Bryan Johnson, become more experimental with our own biological potential. The Dawn of Autonomous Warfare Conflict is undergoing a fundamental rewrite. The era of infantry and massive aircraft carriers is fading, replaced by the rise of drones. The end state is the "autonomous bullet"—self-directed machines that render traditional military structures obsolete. This shift isn't just about technology; it's a change in how humanity perceives power and defense. The side with the superior algorithm wins, fundamentally changing the stakes of global stability. GLP-1: The New Antibiotic We are witnessing the most significant pharmaceutical breakthrough since the discovery of penicillin. GLP-1 drugs are more than weight-loss tools; they are addiction breakers and metabolic resets. By suppressing the urge for overconsumption—whether it's sugar, alcohol, or nicotine—these substances challenge our notions of willpower. While some view obesity as a moral failing, the reality is that we finally have a tool to bend the curve of chronic disease and healthcare costs globally. Embracing this requires shedding old stigmas to prioritize collective well-being. Reclaiming Your Future Growth happens when we align ourselves with reality rather than resisting change. Whether it's advocating for cheaper access to life-saving medicine or understanding the new landscape of technology, the goal remains the same: achieving our highest potential. Step into this new era with an open mind and a commitment to self-discovery.
Mar 25, 2025